Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Androgenetic Alopecia

In brief

The purpose of this study is to determine whether Wharton's Jelly mesenchymal stem cell-derived exosome microneedling on the scalp is an effective treatment for Androgenetic Alopecia (pattern hair loss).

Key facts

Study ID

NCT06482541

Run by

Levit Dermatology

People needed

100

Starts

2024-07-01

Expected to finish

2025-08-01

Last updated by the study team

2024-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participant is experiencing hair loss and is diagnosed with Androgenetic Alopecia.

You may not qualify if…

• Patients cannot have taken any medications, therapies, or treatment modalities of any kind to treat hair loss in the last six months.
• Patients cannot have open wounds, eczema, or psoriatic plaques on the treatment area of the scalp.
• Patients who are undergoing or have undergone chemotherapy and or radiation therapy within the past 6 months
• Patients with a history of an autoimmune bullous disorder (having auto-antibodies to Dsg-1 or Dsg-3)
• Patients who are currently immunocompromised or have a low white count making patients prone to infections.

Where it is running

• Levit Dermatology — Brooklyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.